Development and optimization of topical cyclosporin liposomal gel (2% w/w): double-blind, placebo-controlled clinical trial for efficacy and safety evaluation in patients with stable plaque psoriasis

• In: SIG: Pharmaceutical Biotechnology - Posters
• At: Basel (Switzerland) (2008)
• Type: Poster
• Poster code: PB-P-017
• By: KHURANA, Rajiv Kumar (University Institute of Pharmaceutical Sciences-Panjab University, Chandigarh, India)
• Co-author(s): Dogra, Sunil (Dept. of Dermatology, Post-Graduate Institute of Medical Research, Chandigarh, India)
  Kaur, Inderjeet (Dept of Dermatology, Post-Graduate Institute of Medical Research, Chandigarh, India)
  Bhoop, Bhupinder Singh (University Institute of Pharmaceutical Sciences-Panjab University, CHANDIGARH, India)
  Katare, Om Prakash (University Institute of Pharmaceutical Sciences-Panjab University, CHANDIGARH, India)
  
• Abstract:

  Topical delivery of Cyclosporin A (CysA) is highly desirable for various dermatological diseases including psoriasis. However the horny stratum corneum barrier and the unfavorable physicochemical properties of CysA are the major hicupps.(1) Phospholipid-structured liposomes have been successfully used for cutaneous delivery of several therapeutic..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login